Insider Selling: Beta Bionics (NASDAQ:BBNX) Director Sells 1,406 Shares of Stock

Beta Bionics, Inc. (NASDAQ:BBNX) Director Christy Jones sold 1,406 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $15.00, for a total value of $21,090.00. Following the completion of the sale, the director owned 25,994 shares of the company’s stock, valued at $389,910. This represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christy Jones also recently made the following trade(s):

• On Thursday, June 4th, Christy Jones sold 2,811 shares of Beta Bionics stock. The shares were sold at an average price of $14.00, for a total value of $39,354.00.
• On Thursday, May 21st, Christy Jones sold 1,998 shares of Beta Bionics stock. The shares were sold at an average price of $9.95, for a total value of $19,880.10.

Beta Bionics Stock Up 8.0%

Shares of BBNX stock traded up $1.18 on Thursday, hitting $15.91. The stock had a trading volume of 1,092,973 shares, compared to its average volume of 1,140,386. Beta Bionics, Inc. has a one year low of $8.80 and a one year high of $32.71. The business has a 50 day moving average price of $11.97 and a 200 day moving average price of $15.67. The company has a market cap of $708.95 million, a PE ratio of -10.54 and a beta of 3.40.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.04. The company had revenue of $27.63 million for the quarter. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. Equities research analysts expect that Beta Bionics, Inc. will post -2.22 EPS for the current year.

Institutional Investors Weigh In On Beta Bionics

Several institutional investors have recently bought and sold shares of the company. Eventide Asset Management LLC increased its position in shares of Beta Bionics by 0.8% during the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock worth $152,233,000 after purchasing an additional 37,476 shares in the last quarter. Farallon Capital Management LLC boosted its position in shares of Beta Bionics by 2.6% in the 3rd quarter. Farallon Capital Management LLC now owns 4,313,920 shares of the company’s stock worth $85,718,000 after purchasing an additional 110,000 shares in the last quarter. Soleus Capital Management L.P. grew its stake in Beta Bionics by 12.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after buying an additional 424,817 shares during the last quarter. Vanguard Group Inc. increased its position in Beta Bionics by 213.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after buying an additional 1,509,217 shares in the last quarter. Finally, Eversept Partners LP increased its position in Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock valued at $14,177,000 after buying an additional 736,576 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Wall Street Zen downgraded shares of Beta Bionics from a “hold” rating to a “sell” rating in a research note on Sunday, March 29th. Truist Financial lowered their target price on Beta Bionics from $25.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, April 15th. Stifel Nicolaus cut their price target on Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. The Goldman Sachs Group reduced their price target on Beta Bionics from $19.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, May 27th. Finally, Weiss Ratings downgraded Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $19.70.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.